Hot Topics in Chronic Lymphocytic Leukemia
In this segment, “Hot Topics in Chronic Lymphocytic Leukemia”, William Wierda, MD, PhD, and Susan O’Brien, MD, offer insights into emerging data in CLL.
The progress in CLL therapeutics in the last year has the potential to shift standards of care. In particular, there is exciting data on combination targeted therapies, which have produced high rates of MRD undetectability. Reversible BTK inhibitors may be helpful in patients who have developed resistance to irreversible agents, and longer follow-up is eagerly anticipated. Preliminary data on cellular therapy combinations are emerging.